Healthcare stalwart Merck & Co., Inc. (MRK) continues to strive toward expanding its pipeline. The company recently announced an exclusive license and collaboration agreement with Kelun-Biotech, a clinical-stage biotech company, to develop seven investigational preclinical antibody-drug conjugates (ADC) for cancer treatment.
The agreement grants MRK global licenses to manufacture and commercialize multiple investigational preclinical ADC therapies and exclusive options to obtain additional licenses for ADC candidates.
